|
1.
|
|
12 p, 1.7 MB |
Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
/
Kirschbrown, Whitney. P. (Clinical Pharmacology. Genentech Research and Early Development) ;
Wang, B. (Clinical Pharmacology. Genentech Research and Early Development) ;
Nijem, I. (Clinical Pharmacology. Genentech Research and Early Development) ;
Ohtsu, A. (Department of Gastrointestinal Oncology. National Cancer Center Hospital East) ;
Hoff, P. M. (Instituto do Câncer de São Paulo. Faculdade de Medicina da Universidade de São Paulo) ;
Shah, M. A. (Medical Oncology/Solid Tumor Program. Sandra and Edward Meyer Cancer Center. Weill Cornell Medical College) ;
Shen, L. (Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing). Department of Gastrointestinal Oncology. Peking University Cancer Hospital and Institute) ;
Kang, Y. K. (Department of Oncology. Asan Medical Center. University of Ulsan College of Medicine) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Girish, S. (Clinical Pharmacology. Genentech Research and Early Development) ;
Garg, Amit (Clinical Pharmacology. Genentech Research and Early Development) ;
Universitat Autònoma de Barcelona
Purpose: To characterize the pharmacokinetics (PK) of pertuzumab and trastuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer in the randomized, double-blind, phase III JACOB study (NCT01774786), and to evaluate the appropriateness of the pertuzumab regimen in these patients. [...]
2019 -  10.1007/s00280-019-03871-w
Cancer Chemotherapy and Pharmacology, Vol. 84 Núm. 3 (january 2019) , p. 539-550
|
|
|
2.
|
|
14 p, 4.6 MB |
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
/
De Mattos-Arruda, Leticia (Memorial Sloan Kettering Cancer Center) ;
Ng, Charlotte K. Y. (Department of Biomedicine, University of Basel, Basel, Switzerland) ;
Piscuoglio, Salvatore (University Hospital Basel (Basilea, Suïssa)) ;
Gonzalez-Cao, Maria (Grup Quirónsalud (Barcelona, Catalunya)) ;
Lim, Raymond S. (Memorial Sloan Kettering Cancer Center) ;
De Filippo, Maria R. (Memorial Sloan Kettering Cancer Center) ;
Fusco, Nicola (Memorial Sloan Kettering Cancer Center) ;
Schultheis, Anne M. (Memorial Sloan Kettering Cancer Center) ;
Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Viteri, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Macedo, Gabriel S. (Memorial Sloan Kettering Cancer Center) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Gómez, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Teixidó, Cristina (Grup Quirónsalud (Barcelona, Catalunya)) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Tresserra Casas, Francesc (Grup Quirónsalud (Barcelona, Catalunya)) ;
Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ;
Cortés, Javier (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats) ;
Reis-Filho, Jorge S. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to define the repertoire of mutations private to or enriched for in HER2-positive brain metastases. [...]
2018 - 10.18632/oncotarget.25041
Oncotarget, Vol. 9 (april 2018) , p. 20617-20630
|
|
|
3.
|
|
14 p, 6.9 MB |
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
/
Hergueta-Redondo, Marta (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Sarrio, David (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Molina-Crespo, Ángela (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Vicario, Rocío (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bernadó Morales, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez, Lidia (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Rojo-Sebastián, Alejandro (Pathology Department, MD Anderson Cancer Center, Madrid, Spain) ;
Serra-Musach, Jordi (Institut d'Investigació Biomèdica de Bellvitge) ;
Mota, Alba (Translational Research Laboratory, MD Anderson Internacional Foundation, Madrid, Spain) ;
Martínez-Ramírez, Ángel (Cytogenetics Department, MD Anderson Cancer Center, Madrid, Spain) ;
Castilla, Maria Ángeles (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
González-Martin, Antonio (Oncology Department, MD Anderson Cancer Center, Madrid, Spain) ;
Pernas, Sonia (Institut d'Investigació Biomèdica de Bellvitge) ;
Cano, Amparo (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Cortés, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Nuciforo, Paolo. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Palacios, José (Hospital Universitario Ramón y Cajal (Madrid)) ;
Pujana, Miguel Ángel (Institut d'Investigació Biomèdica de Bellvitge) ;
Arribas, Joaquín V (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Moreno-Bueno, Gema (Translational Research Laboratory, MD Anderson Internacional Foundation, Madrid, Spain) ;
Universitat Autònoma de Barcelona
Around, 30-40% of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially unknown. Interestingly, ERBB2 is frequently co-amplified and co-expressed with neighbour genes that may play a relevant role in this cancer subtype. [...]
2016 - 10.18632/oncotarget.10787
Oncotarget, Vol. 7 (july 2016) , p. 56295-56308
|
|
|
4.
|
|
9 p, 234.9 KB |
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer : results from the GEICAM/2006-14 trial
/
Alba, Emilio (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Albanell Mestres, Joan (Parc de Salut MAR de Barcelona) ;
de la Haba Rodríguez, Juan Rafael (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Calvo, L.. (Complejo Hospitalario Universitario de A Coruña) ;
Sánchez-Rovira, P. (Complejo Hospitalario de Jaén) ;
Ramos, M. (Centro Oncológico de Galicia) ;
Rojo, F. (Hospital Universitario Fundación Jiménez Díaz) ;
Burgués, Octavio (Hospital Clínic Universitari (València)) ;
Carrasco, E. (Grupo GEICAM de Investigación en Cáncer de Mama) ;
Caballero, Rosalía (Grupo GEICAM de Investigación en Cáncer de Mama) ;
Porras, I (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
Cámara, M. C. (Grupo GEICAM de Investigación en Cáncer de Mama) ;
Lluch, Ana (Hospital Clínic Universitari (València)) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. [...]
2014 - 10.1038/bjc.2013.831
British Journal of Cancer, Vol. 110 (01 2014) , p. 1139-1147
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
